Mezigdomide
A pharmaceutical drug used in cancer treatment
| Mezigdomide | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Mezigdomide is a pharmaceutical drug that is primarily used in the treatment of certain types of cancer. It belongs to a class of drugs known as immunomodulatory drugs (IMiDs), which are known for their ability to modulate the immune system and inhibit tumor growth.
Mechanism of Action[edit | edit source]
Mezigdomide functions by modulating the activity of the immune system. It binds to the protein cereblon, which is part of the E3 ubiquitin ligase complex. This binding leads to the degradation of specific transcription factors that are essential for the survival and proliferation of cancer cells. By targeting these proteins, Mezigdomide can induce apoptosis, or programmed cell death, in cancer cells, thereby reducing tumor growth.
Clinical Uses[edit | edit source]
Mezigdomide is used in the treatment of various hematological malignancies, including multiple myeloma and certain types of lymphoma. It is often used in combination with other chemotherapeutic agents to enhance its efficacy. The drug is administered orally, making it a convenient option for patients.
Side Effects[edit | edit source]
Like many cancer treatments, Mezigdomide can cause a range of side effects. Common side effects include fatigue, nausea, and diarrhea. More serious side effects can include neutropenia, which is a decrease in white blood cells, increasing the risk of infection. Patients are monitored closely for these side effects during treatment.
Development and Approval[edit | edit source]
Mezigdomide was developed as part of ongoing research into IMiDs, following the success of earlier drugs in this class such as thalidomide and lenalidomide. It has undergone extensive clinical trials to establish its safety and efficacy in treating cancer. The drug received approval from regulatory agencies after demonstrating significant benefits in clinical outcomes for patients with specific types of cancer.
Research and Future Directions[edit | edit source]
Ongoing research is exploring the potential of Mezigdomide in treating other types of cancer and in combination with new therapeutic agents. Studies are also investigating its role in modulating the immune system in other diseases beyond cancer.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
